Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 112; no. 46; pp. 14325 - 14330
• Main Authors: Tolaney, Sara M., Boucher, Yves, Duda, Dan G., Martin, John D., Seano, Giorgio, Ancukiewicz, Marek, Barry, William T., Goel, Shom, Lahdenrata, Johanna, Isakoff, Steven J., Yeh, Eren D., Jain, Saloni R., Golshan, Mehra, Brock, Jane, Snuderl, Matija, Winer, Eric P., Krop, Ian E., Jain, Rakesh K.
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 17.11.2015; National Acad Sciences
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Bevacizumab - administration & dosage; Biological Sciences; Biomarkers, Tumor - metabolism; Biopsy; Blood vessels; Breast cancer; Breast Neoplasms - blood supply; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Chemotherapy; Confidence intervals; Density; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - metabolism; Neovascularization, Pathologic - pathology; antiangiogenic therapy; circulating and tissue biomarkers; PAM50 gene signature; cellular proliferation

Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC) patients. To explore potential mechanisms of this benefit, we conducted a phase II study of neoadjuvant bevacizumab (single dose) followed by combined bevacizumab and adriamycin/cyclophosphamide/paclitaxel chemother...